Table 3.
Correlation between Serum Lipids Concentrations and Clinical and Laboratory Data in Patients with AD (P-Values)
| BMI | BSA | EASI | SCORAD | Pruritus | Sleeplessness | Eosinophils | Total IgE | TARC | |
|---|---|---|---|---|---|---|---|---|---|
| Sph | 0.65 | 0.032 | 0.11 | 0.11 | 0.44 | 0.57 | 0.65 | 0.50 | 0.032 |
| SM(12:0) | 0.70 | 1.00 | 1.00 | 0.81 | 0.52 | 0.65 | 0.92 | 0.94 | 0.93 |
| SM(14:0) | 0.68 | 0.95 | 0.94 | 0.94 | 1.00 | 0.44 | 0.56 | 0.59 | 0.94 |
| SM(16:0) | 0.89 | 0.52 | 0.57 | 0.69 | 1.00 | 0.60 | 0.81 | 0.43 | 0.65 |
| SM(18:1) | 0.35 | 0.63 | 0.59 | 0.60 | 0.49 | 0.60 | 0.92 | 0.97 | 0.92 |
| SM(18:0) | 0.35 | 0.94 | 0.94 | 1.00 | 0.97 | 1.00 | 0.78 | 0.93 | 0.93 |
| SM(20:0) | 0.66 | 0.96 | 0.96 | 0.94 | 0.81 | 0.67 | 0.60 | 0.68 | 0.92 |
| SM(22:0) | 0.73 | 0.98 | 0.92 | 0.97 | 0.92 | 0.74 | 0.83 | 0.97 | 0.92 |
| SM(24:1) | 0.65 | 0.83 | 0.93 | 0.94 | 0.92 | 0.83 | 0.92 | 0.50 | 0.83 |
| SM(24:0) | 0.98 | 1.00 | 0.78 | 0.99 | 0.81 | 0.68 | 0.93 | 0.93 | 1.00 |
| PC(28:0) | 1.00 | 1.00 | 0.94 | 0.92 | 0.60 | 0.43 | 1.00 | 0.57 | 0.94 |
| PC(30:0) | 0.92 | 1.00 | 0.98 | 0.92 | 0.72 | 0.52 | 0.96 | 0.70 | 0.97 |
| PC(30:1) | 0.92 | 0.81 | 0.94 | 0.93 | 0.98 | 0.70 | 0.81 | 0.60 | 0.93 |
| PC(32:0) | 0.65 | 0.97 | 0.93 | 0.94 | 1.00 | 0.74 | 0.91 | 0.97 | 0.94 |
| PC(32:1) | 0.60 | 0.43 | 0.59 | 0.73 | 1.00 | 0.97 | 0.85 | 0.73 | 0.63 |
| PC(34:1) | 0.83 | 0.15 | 0.15 | 0.43 | 0.93 | 0.96 | 0.60 | 0.28 | 0.43 |
| PC(34:2) | 0.43 | 1.00 | 0.92 | 1.00 | 0.93 | 0.83 | 0.98 | 0.94 | 0.91 |
| PC(36:0) | 0.60 | 0.35 | 0.43 | 0.81 | 0.52 | 0.72 | 0.92 | 0.39 | 0.57 |
| PC(36:1) | 0.82 | 0.96 | 0.73 | 0.98 | 1.00 | 0.92 | 0.92 | 0.92 | 1.00 |
| PC(36:2) | 0.73 | 0.73 | 0.57 | 0.92 | 0.98 | 0.92 | 0.76 | 0.94 | 0.93 |
| PC(36:4) | 0.86 | 0.63 | 0.44 | 0.81 | 0.83 | 0.57 | 0.66 | 0.94 | 1.00 |
| PC(38:1) | 0.92 | 0.96 | 0.79 | 0.94 | 0.59 | 0.43 | 0.98 | 0.60 | 0.83 |
| PC(38:2) | 0.74 | 0.72 | 0.78 | 0.92 | 0.97 | 0.89 | 1.00 | 0.81 | 1.00 |
| PC(38:3) | 0.44 | 0.63 | 0.44 | 0.78 | 1.00 | 0.94 | 0.59 | 0.92 | 0.94 |
| PC(38:4) | 0.18 | 0.25 | 0.11 | 0.44 | 0.74 | 0.44 | 0.43 | 0.92 | 0.85 |
| LPC(16:0) | 0.39 | 0.26 | 0.39 | 0.74 | 1.00 | 0.97 | 0.93 | 0.34 | 0.39 |
| LPC(16:1) | 0.26 | 0.52 | 0.65 | 0.81 | 0.81 | 0.93 | 0.83 | 0.61 | 0.60 |
| LPC(18:0) | 0.34 | 0.52 | 0.60 | 1.00 | 0.93 | 0.63 | 1.00 | 0.57 | 0.60 |
| LPC(18:1) | 0.94 | 0.94 | 1.00 | 0.93 | 0.93 | 0.44 | 0.93 | 0.57 | 0.78 |
| LPC(18:2) | 0.49 | 0.45 | 0.45 | 0.43 | 0.89 | 0.39 | 0.60 | 0.96 | 0.60 |
| LPC(20:1) | 0.99 | 0.90 | 0.88 | 0.94 | 0.97 | 0.76 | 1.00 | 0.81 | 0.68 |
| LPC(20:3) | 0.11 | 0.63 | 0.92 | 0.93 | 0.91 | 0.92 | 0.52 | 0.57 | 0.92 |
| LPC(20:4) | 0.15 | 0.52 | 0.57 | 0.70 | 0.68 | 0.94 | 0.52 | 0.50 | 0.92 |
| LPE(16:0) | 0.59 | 0.93 | 0.94 | 0.94 | 0.66 | 0.43 | 0.97 | 0.92 | 0.68 |
| LPE(18:0) | 0.25 | 0.60 | 0.52 | 0.99 | 0.43 | 0.92 | 0.94 | 0.97 | 0.35 |
| LPE(18:1) | 0.73 | 0.82 | 0.63 | 0.57 | 0.81 | 0.83 | 0.97 | 0.65 | 0.97 |
| LPE(18:2) | 1.00 | 0.65 | 0.52 | 0.43 | 0.74 | 0.43 | 0.72 | 0.83 | 0.83 |
| LPE(20:4) | 0.26 | 0.82 | 0.94 | 1.00 | 0.98 | 0.59 | 0.86 | 0.94 | 0.94 |
| Lyso-PAF | 0.61 | 0.60 | 0.52 | 0.93 | 0.82 | 0.63 | 0.94 | 0.43 | 0.64 |
| Cer(16:0) | 0.57 | 0.74 | 0.91 | 0.43 | 0.59 | 0.81 | 0.60 | 0.39 | 0.92 |
Abbreviations: AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; Cer, ceramide; EASI, eczema area and severity index; Ig, immunoglobulin; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PAF, platelet-activating factor; PC, phosphatidylcholine; SCORAD, severity scoring of atopic dermatitis; SM, sphingomyelin; Sph, sphingosine; TARC, thymus and activation regulated chemokine.
We analyzed the correlation between serum lipids concentrations and clinical and laboratory data in patients with AD (n = 179). The ρ values were calculated by Spearman's correlation test, and the P-values were adjusted using Benjamini‒Hochberg procedure. Table 3 shows the P-values supporting Figure 2.